MADRID, Spain—ClinTec International, a full-service, global contract research organization (CRO) headquartered in the United Kingdom, has announced the opening of two new offices in Spain and the appointment of Carlos Palacios as the company’s new regional manager for Spain and Portugal. The company, which provides support to the pharmaceutical, biotechnology and medical device industry, operates in more than 50 countries.
The announcement said that ClinTec is “adding significant depth of capability to Spain and Portugal as a key target market in Europe, moving to a larger office in Barcelona, opening a new office in Madrid and strengthening the management team with the appointment of Carlos Palacios as regional manager.”
The CRO has added the new regional management post because of the growth of the Spain-based team and added the offices to enable the expansion of the local clinical trial portfolio and larger functional outsourcing engagements in Spain.
ClinTec International offers customized clinical research solutions for drug development. The award-winning company specializes in clinical research for immuno-oncology and rare diseases. A woman-owned private company, ClinTec works with seven of the top 10 pharmaceutical companies in the world, as well as biotechnology and medical device firms. It conducts Phase 1 to Phase 4 clinical studies in oncology, rare diseases, neurology, autoimmune diseases and diabetes. It has supported clinical development in cardiovascular disease, dermatology, endocrine and metabolic disorders, gastrointestinal disease, genetic disorders, hematology, hepatobiliary, immunology and infectious diseases. Its repertoire also includes work in medical devices, nephrology, neurology, nutrition, oncology, orthopedics, pediatrics, psychiatry, respiratory, rheumatology, transplant medicine, urology, vaccine programs, virology and women’s health.
Bobby Bal, chief commercial officer and executive vice president for the company, said, “ClinTec has a strong heritage in Europe, and we are executing on our plan to provide even greater depth of capability within the key European markets. Our recent expansion in Spain highlights our ongoing commitment to address the growing needs of our loyal client base, including the delivery of complex class-leading oncology programs. It is an exciting time at ClinTec as we seek to keep innovating and investing within our solutions and capabilities.”
ClinTec’s key clinical research service areas are full-service outsourcing, functional service provider solutions, patient recruitment and retention, education and training and clinical supplies and packaging. In addition to diverse therapeutic experience, the company specializes in orphan indications, bioequivalence and bioavailability studies and medical devices.
According to the CEO and founder of ClinTec International, Dr. Rabinder Buttar, “We have now entered a new phase of development and are on track to scale the organization considerably in the next 12 months as we enter our 20th year of growth. The creation of the new regional management post and the opening of the two new offices in Madrid and Barcelona signal that ClinTec is developing and expanding in line with our current clients’ needs, and that as a company, we are ready to take on new business of all sizes. I am delighted that Carlos has joined our team at ClinTec as we continue to expand our business in the Spanish and Portuguese region.”
